Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505439 | 0.87 | CYP2A6 (0.40) | CYP2A6PTPN1 | |
| SCHEMBL1505438 | 0.87 | CYP2A6 (0.38) | CYP2A6FLT3TYRO3MERTKGAS6 | |
| SCHEMBL2132019 | 0.86 | CYP2A6 (0.38) | CYP2A6 | |
| SCHEMBL2135487 | 0.86 | CYP2A6 (0.38) | CYP2A6FLT3TYRO3MERTKGAS6 | |
| SCHEMBL1505661 | 0.85 | CYP2A6 (0.39) | CYP2A6FLT3TYRO3MERTKGAS6 | |
| SCHEMBL31511983 | 0.85 | CYP2A6 (0.40) | CYP2A6 | |
| SCHEMBL2136584 | 0.85 | CYP2A6 (0.40) | CYP2A6 | |
| SCHEMBL1505470 | 0.85 | CYP2A6 (0.39) | CYP2A6PTPN1 | |
| SCHEMBL2132176 | 0.84 | CYP2A6 (0.37) | CYP2A6TP53MAPTPTPN1 | |
| SCHEMBL2134933 | 0.84 | SMN1; SMN2 (0.41) | CYP2A6FLT3TYRO3MERTKGAS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | CYP2A6 754/4885FLT3 115/4885TYRO3 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.